• Record sales orders of $34.9 million, up 6% on H1 FY25
• Reported revenue up 32% to $30.8 million, driven by improved execution
• Progressing $2 million p.a. cost-out program to lift operating leverage

Compumedics Ltd has delivered a strong H1 FY26 performance, reporting record sales orders of $34.9 million, up 6% on H1 FY25, and record shipped revenue of $30.8 million, up 32% on the prior period. The improved results reflect strengthening demand and better conversion across the company's core sleep and neuro platforms, following a targeted commercial refocus in the USA. The company secured one MEG order in H1 FY26, with further MEG opportunities expected to progress in H2. Compumedics is progressing a $2 million per annum cost-out program to lift operating leverage and support margin expansion, while maintaining investment in priority growth initiatives. The program is focused on structural efficiency, reduced overhead intensity and stronger capital discipline, with benefits expected to build through H2 FY26. Compumedics' H1 FY26 EBITDA is expected to exceed $3 million. The company reaffirmed its FY26 guidance of $70 million in revenue and up to $9 million in EBITDA, with a stronger second half profile expected, underpinned by improving shipment conversion, the progressive impact of the cost-out program, and high-value product and pipeline catalysts, including the launch of Somfit D in H2 FY26 and advancing MEG opportunities.

FY26 revenue guidance: $70 million FY26 EBITDA guidance: up to $9 million

The company expects a stronger second half in FY26, underpinned by improving shipment conversion, the progressive impact of the cost-out program, and high-value product and pipeline catalysts, including the launch of Somfit D in H2 FY26 and advancing MEG opportunities.